Welcome to our dedicated page for Larimar Therapeutics news (Ticker: LRMR), a resource for investors and traders seeking the latest updates and insights on Larimar Therapeutics stock.
Larimar Therapeutics, Inc. (Nasdaq: LRMR) is a clinical-stage biotechnology company dedicated to developing innovative treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently undergoing Phase 1 clinical trials as a potential treatment for Friedreich’s ataxia, a progressive genetic disorder. Using its proprietary cell-penetrating peptide technology platform, Larimar aims to design fusion proteins that address deficiencies in intracellular bioactive compounds.
CTI-1601, a subcutaneously administered, recombinant fusion protein, is engineered to deliver human frataxin (FXN) directly to the mitochondria in patients with Friedreich’s ataxia. This approach is intended to mitigate the symptoms of this debilitating disease, offering hope to patients and their families.
Larimar Therapeutics reported a net loss of $9.1 million in Q3 2023, with research and development expenses totaling $6.6 million. The increase in expenses is attributed to ongoing clinical trials, personnel costs, and professional fees. The company had $95.6 million in cash, cash equivalents, and marketable securities as of September 30, 2023, ensuring sufficient liquidity into Q1 2025.
Recent activities include initiating an underwritten public offering of common stock and pre-funded warrants to raise funds for further research and development, particularly for the continued progression of CTI-1601.
Partnerships with financial entities such as Leerink Partners, Citigroup, and Guggenheim Securities have bolstered Larimar's market presence, demonstrating strong investor confidence and commitment to its mission.
For more information, visit Larimar Therapeutics, Inc.
Larimar Therapeutics (Nasdaq: LRMR) announced that CEO Carole Ben-Maimon will participate in the William Blair Biotech Focus Conference 2021, scheduled virtually for July 14-15. Dr. Ben-Maimon will engage in a fireside chat on July 15 at 3:00 PM ET, discussing the company's development of treatments for complex rare diseases. Larimar's lead candidate, CTI-1601, is being evaluated for Friedreich's ataxia in a Phase 1 program. A replay of the chat will be accessible on Larimar's website.
Larimar Therapeutics (Nasdaq: LRMR) announced that CEO Carole Ben-Maimon will present at the JMP Securities Life Sciences Conference on June 16-17, 2021. The presentation will take the form of a fireside chat scheduled for 2:00 PM ET on June 16. Larimar focuses on developing treatments for rare diseases, currently evaluating its lead compound, CTI-1601, in a Phase 1 clinical program for Friedreich’s ataxia. The company aims to utilize its platform for creating fusion proteins targeting additional rare diseases.
Larimar Therapeutics (Nasdaq: LRMR) announced a clinical hold by the FDA on its CTI-1601 program due to mortalities observed in a non-human primate toxicology study. The company will not proceed with its planned private placement financing. CEO Carole Ben-Maimon emphasized patient safety and confirmed ongoing evaluation of data to comply with FDA requirements, potentially delaying upcoming trials into 2022. Larimar has $81.4 million in cash, sufficient for operations through mid-2022, and continues to believe in a viable path for CTI-1601’s development.
Larimar Therapeutics (Nasdaq: LRMR) announced a private placement financing raising approximately $95 million. The transaction involves the issuance of around 7,096,048 shares at a price of $13.43 per share. The funds will support the clinical development of CTI-1601, a treatment for Friedreich's ataxia, and other corporate purposes. Notable investors include Deerfield Management and RA Capital Management. The placement is expected to close by May 25, 2021.
Larimar Therapeutics (Nasdaq: LRMR) announced that the European Medicines Agency granted Priority Medicines (PRIME) designation for CTI-1601, a recombinant fusion protein aimed at treating Friedreich’s ataxia (FA). This designation comes after positive data from nonclinical and Phase 1 clinical studies, indicating that CTI-1601 can deliver human frataxin effectively. Larimar also holds multiple designations from the FDA, facilitating its development process. The company plans to initiate further clinical trials in the latter half of the year, enhancing its position in addressing rare diseases.
Larimar Therapeutics announced promising results from its Phase 1 clinical trial of CTI-1601, aimed at treating Friedreich's ataxia. The study demonstrated that daily subcutaneous injections over 13 days significantly increased frataxin levels in various tissues compared to placebo, achieving levels similar to healthy carriers. Safety data indicated that CTI-1601 was well tolerated without serious adverse events. The company plans future trials, including a pediatric study. This breakthrough could address critical unmet needs in FA treatment.
Larimar Therapeutics (Nasdaq: LRMR) reported its Q1 2021 results, highlighting significant progress in its Phase 1 trial for Friedreich's ataxia (FA). The company has cash and investments amounting to $81.4 million as of March 31, 2021, with a net loss of $12.1 million or $0.76 per share. The increase in R&D expenses to $9.0 million reflects higher clinical costs and personnel hiring. Management announced that topline data from the Phase 1 study will be revealed on May 11, 2021, which will include crucial pharmacodynamic data.
Learmar Therapeutics, Inc. (Nasdaq: LRMR) reported its preliminary Phase 1 findings for CTI-1601, a treatment for Friedreich's ataxia, indicating safety and tolerability in doses up to 100 mg. The company holds $92.6 million in cash as of December 31, 2020, despite a net loss of $42.5 million for the year, reflecting increased R&D costs due to clinical trials and personnel. Topline data from ongoing placebo-controlled trials is anticipated in Q2 2021, alongside the initiation of new trials aimed at further advancing CTI-1601's development.
BALA CYNWYD, Pa., Feb. 18, 2021 – Larimar Therapeutics (Nasdaq: LRMR) announced that Dr. Carole Ben-Maimon, CEO, will present at the SVB Leerink 10th Annual Global Healthcare Conference from February 22-26, 2021. The presentation is scheduled for February 26, 2021, at 8:00 AM ET, in a fireside chat format. Larimar is a clinical-stage biotech firm focused on therapies for rare diseases, notably evaluating CTI-1601 for Friedreich’s ataxia. More information can be found via their website.
Larimar Therapeutics has been added to the NASDAQ Biotechnology Index effective December 21, 2020. This index tracks biotechnology and pharmaceutical companies on the NASDAQ exchange. Larimar, focusing on treatments for complex rare diseases, is developing its lead compound, CTI-1601, for Friedreich’s ataxia. The index’s recognition may enhance visibility and potentially attract more investors to Larimar, reflecting its active involvement in the biotechnology sector.
FAQ
What is the current stock price of Larimar Therapeutics (LRMR)?
What is the market cap of Larimar Therapeutics (LRMR)?
What is Larimar Therapeutics’ primary focus?
What is the lead compound of Larimar Therapeutics?
What stage is CTI-1601 currently in?
What is Friedreich’s ataxia?
How does CTI-1601 work?
What recent financial achievement did Larimar Therapeutics report?
What are Larimar Therapeutics' expansion plans?
Who are Larimar’s financial partners?
What are the next steps for Larimar’s public offering?
Where can I find more information about Larimar Therapeutics?
